Terms ending in 2028
Every in-force patent on Intervet Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,980,283 | C. perfringens alpha toxoid vaccine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 7,732,187 | Recombinant Attenuated Clostridium Organisms and Vaccine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 9,593,303 | Method for Continuously Culturing Ehrlichia and Neorickettsia Risticii In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 12,324,657 | System And Method for Diagnosis Of Bovine Diseases Using Auscultation Analysis In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 8,791,242 | Canine Thymic Stromal Lymphopoietin Protein and Uses Thereof to Treat Allergic Symptoms In force · High confidence | Intervet Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.